Exploring the link between renalase levels and blood flow issues in heart attack patients after treatment
Correlation of Blood Serum Renalase and Microcirculation Obstruction in Patients with Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention
This study is testing if measuring renalase levels in heart attack patients can help us understand blood flow problems they might have after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Third Xiangya Hospital of Central South University Academic / other |
| Locations | 1 site (Changsha, Hunan) |
| Trial ID | NCT06669520 on ClinicalTrials.gov |
What this trial studies
This research investigates the relationship between blood serum renalase levels and microcirculation obstruction in patients who have experienced an acute myocardial infarction (AMI) following primary percutaneous coronary intervention (PCI). The study aims to identify potential risk factors that contribute to microcirculation obstruction in these patients. By analyzing serum renalase levels, the researchers hope to gain insights into the underlying mechanisms affecting blood flow after heart attacks. This observational study will include patients who meet specific criteria related to the timing and severity of their heart attack.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have experienced a STEMI or high-risk NSTEMI and are undergoing emergency PCI.
Not a fit: Patients with non-obstructive acute myocardial infarction or severe chronic kidney disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help identify risk factors for microcirculation obstruction, potentially leading to improved treatment strategies for heart attack patients.
How similar studies have performed: While this specific approach is novel, similar studies have explored the role of biomarkers in myocardial infarction outcomes, indicating potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 years; 2. STEMI symptom onset time \< 12 hours; 3. STEMI symptom onset time 12-48 hours with persistent ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias; 4. High-risk NSTEMI; 5. Emergency PCI; 6. Voluntary informed consent. Exclusion Criteria: 1. Non-obstructive acute myocardial infarction; 2. Severe chronic kidney disease (defined as estimated glomerular filtration rate \< 20 mL/min per 1.73 m²); 3. Life expectancy \< 1 year; 4. Pregnant or planning to become pregnant; 5. Emergency PCI failure.
Where this trial is running
Changsha, Hunan
- The Third Xiangya Hospital of Central South University — Changsha, Hunan, China (Recruiting)
Study contacts
- Study coordinator: Weihong Jiang
- Email: jiangweihongdoc@163.com
- Phone: （86）13786113632
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.